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Dysregulation of the calcitonin gene-related peptide
(CGRP), a potent vasodilator, is directly implicated
in the pathogenesis of migraine. CGRP binds to
and signals through the CGRP receptor (CGRP-R),
a heterodimer containing the calcitonin receptor-
like receptor (CLR), a class B GPCR, and RAMP1, a
receptor activity-modifying protein. We have solved
the crystal structure of the CLR/RAMP1 N-terminal
ectodomain heterodimer, revealing how RAMPs
bind to and potentially modulate the activities of
the CLR GPCR subfamily. We also report the struc-
tures of CLR/RAMP1 in complex with the clinical
receptor antagonists olcegepant (BIBN4096BS) and
telcagepant (MK0974). Both drugs act by blocking
access to the peptide-binding cleft at the interface
of CLR and RAMP1. These structures illustrate, for
the first time, how small molecules bind to andmodu-
late the activity of a class B GPCR, and highlight the
challenges of designing potent receptor antagonists
for the treatment of migraine and other class B
GPCR-related diseases.
INTRODUCTION
CGRP is a 37-amino acid neuropeptide belonging to a family of
related hormones that also includes calcitonin, adrenomedullin,
and amylin. One of themost potent vasodilators known, CGRP is
found widely in both the central and peripheral nervous systems,
and is the major neuropeptide of the trigeminovascular system.
CGRP is expressed at trigeminal nerve endings that innervate
cerebral blood vessels, and this localization, its vasodilatory
effect, and other evidence suggest a direct role of CGRP in
migraine (Doods et al., 2007; Link et al., 2008). For example, early
studies showedCGRP at elevated levels in jugular venous blood,
but not in peripheral blood (Goadsby et al., 1990), and infusion of
exogenous CGRP into migraine-susceptible patients causes
headache and migraine-like disorders (Lassen et al., 2002).
Recent data from clinical trials with the CGRP antagonists olce-Structure 18, 1083–10gepant (BIBN409BS6) (Olesen et al., 2004) and telcagepant
(MK0974) (Ho et al., 2008a) show that these agents are effica-
cious in treating acute migraine.
Understanding the mechanisms of CGRP receptor activation
by CGRP peptide, and conversely antagonism by small mole-
cules and peptides, is difficult due to the complex nature of the
target. CGRP receptor (CGRP-R) consists of two protein compo-
nents, CLR and RAMP1. CLR, the calcitonin receptor-like
receptor, is a class B GPCR. This class, also known as the
hormone, or secretin-like receptors, all bind polypeptide
hormones of 27–141 amino acids, possess a structured
N-terminal extracellular domain (ECD) or ectodomain, a seven
helix transmembrane (7-TM) domain, and an intracellular
carboxyl terminus. Other members of this class include recep-
tors for secretin, glucagon, vasoactive intestinal peptide (VIP),
parathyroid hormone (PTH), corticotropin-releasing factor
(CRF), pituitary adenylate cyclase-activating peptide (PACAP),
and calcitonin (CTR). Structures of several ECDs have been
solved by X-ray crystallography or NMR spectroscopy, and all
possess a common abba folding topology stabilized by
three conserved disulfide pairs (Grace et al., 2004, 2007; Pioszak
et al., 2008; Pioszak and Xu, 2008; Runge et al., 2008; Sun et al.,
2007). Several ECD structures have been solved with peptides
bound (Grace et al., 2007; Pioszak et al., 2008; Pioszak and
Xu, 2008; Runge et al., 2008; Sun et al., 2007); however, no struc-
tures have been reported with either small molecule agonists or
antagonists bound to any class B GPCR.
A subset of class BGPCRs, including CTR and CLR, formmul-
timeric complexes with receptor activity-modifying proteins, or
RAMPs (McLatchie et al., 1998). The three knownRAMPproteins
all contain a cleavable signal peptide, N-terminal extracellular
domain, single transmembrane helix, and an intracellular
C-terminal domain. Combinations of the three RAMP proteins
with CLR confer specificity for different signaling peptides. For
example, the heterodimer consisting of CLR and RAMP1 is
specific for CGRP, while CLR/RAMP2 and CLR/RAMP3 are
adrenomedullin receptors. In addition, CTR combined with
each of the three RAMP proteins forms three distinct amylin
receptor subtypes. While both the RAMP (Kuwasako et al.,
2003) and CLR (Ittner et al., 2005; Koller et al., 2002) N-terminal
sequences clearly determine specificity for peptide agonists,
several studies have also implicated them as important determi-
nants for antagonist binding (Hay et al., 2006; Mallee et al., 2002;93, September 8, 2010 ª2010 Elsevier Ltd All rights reserved 1083
Figure 1. Structure of the CLR/RAMP1
Ectodomain Complex
(A) Ribbon diagram of CLR (cyan) and RAMP1
(magenta). Disulfide bonds are shown in yellow.
Helices in RAMP are labeled aR1–aR3, and the
single helix in CLR is labeled aC1.
(B) The CLR-RAMP1 interface. Detailed interac-
tions of CLR helix aC1 with helices aR2 and aR3
and the C-terminal loop region (102–108) of
RAMP1 are shown. Protein side-chain carbons
are colored cyan and magenta for CLR and
RAMP1, respectively. Protein heteroatoms are
colored: O, red; N, blue; S, yellow.
(C) Surface representation of the CLR/RAMP1
complex. Key residues on RAMP1 are labeled in
white, while residues on CLR are labeled in black.
Surfaces of charged residues are shown in red (-)
and blue (+). The C-terminal tail (amber) of
RAMP1 from one symmetry-related CLR/RAMP1
complex binds at the CLR-RAMP1 interface of
the adjacent CLR/RAMP1. The C-terminal
RAMP1 ‘‘tail peptide’’ sequence shown corre-
sponds to residues 105–117 (PISGRAVRDPPGS).
Two sulfate ions bind near CLR Thr122 and one
sulfate binds in the hydrophobic pocket defined
by RAMP residues Trp74 and Trp84. Formation
of the CLR/RAMP1 complex results in a buried
surface area of 1032.1 A˚2 for the heterodimer.
Details regarding crystallization, structure deter-
mination and refinement are provided in the
Experimental Procedures and Table 1.
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Crystal Structure of the CGRP Receptor ECD ComplexSalvatore et al., 2006). Based on these observations, and
previous chemical crosslinking studies (Hilairet et al., 2001), it
was suggested that both proteins together form the antagonist
binding pocket.
Aswithmost GPCRs, biochemical and biophysical analyses of
the CGRP receptor are difficult due to the membrane-bound
nature of the target and the lack of an abundant natural source
from which protein may be purified. Recombinant expression
and purification are complicated further by the functional
requirement of a dimeric receptor, and the presence of multiple
disulfide bonds in both CLR and RAMP1. To address these
challenges, a reductionist approach was used to express and
purify a stable, functional binary complex of the extracellular
domains of CLR and RAMP1. N-terminal ectodomain constructs
of CLR and RAMP1 were expressed separately as inclusion
bodies in Escherichia coli, but refolded together to form a 1:1
complex. This ectodomain complex was competent to bind
CGRP, as well as both peptide and small molecule antagonists
(Koth et al., 2010). Here, we report the crystallographic struc-
tures of the ectodomain complexes of the CGRP receptor in
the unliganded state, as well as with the potent, clinically vali-
dated CGRP receptor antagonists olcegepant and telcagepant.
RESULTS AND DISCUSSION
Structure of the CGRP Receptor Ectodomain Complex
The crystal structure of the CLR/RAMP1 ectodomain complex in
the unliganded state is shown in Figure 1. In the complex with
RAMP1, CLR has an overall fold with some features similar to
those found in other class B GPCR ectodomain structures
(Grace et al., 2004, 2007; Parthier et al., 2007; Pioszak et al.,1084 Structure 18, 1083–1093, September 8, 2010 ª2010 Elsevier Lt2008; Pioszak and Xu, 2008; Runge et al., 2008; Sun et al.,
2007). Observable density at the N terminus of CLR begins at
residue 29 and forms a helix (labeled aC1) from residues
35–53. This CLR helix packs against helices aR2 and aR3 of
the three-helix bundle of RAMP1. The aC1 helix length and
positioning in CLR is very similar to that observed for both the
PTH receptor (Pioszak and Xu, 2008) and the GIP receptor
(Parthier et al., 2007) (Figure 2), but differs considerably from
the very short helical stretch seen in the CRFR1 (Pioszak et al.,
2008) and CRFR2 (Grace et al., 2004, 2007) receptor ectodo-
mains. A long loop of irregular secondary structure (residues
55–64) follows, leading to a long finger-like motif from residues
65–81. This finger-like structural motif, stabilized by a pair of
disulfide bonds between Cys48-Cys74 and Cys65-Cys105, is
conserved across all ectodomain structures. At the tip of the
finger is Trp 72, a key residue involved in binding small molecule
antagonists. Following the Trp finger is a two-stranded antipar-
allel b sheet. In the orientation shown (Figure 1A), the loop
between strands 1 and 2 defines the base of the ligand binding
site, and presumably is closest to the 7-TM domain of CLR.
While the finger-like motif is common among the class B ECD
structures, other elements of secondary structure vary, for
example, the lengths of helices (analogous to helix aC1 of
CLR), the presence of additional short helical motifs, and the
lengths and conformations of loop structures. These features
may provide an additional basis for conferring specificity as
well as potential sites for allosteric modulation.
The RAMP1 domain contains a three helix bundle, aligned
roughly perpendicular to helix aC1 of CLR. Starting from the N
terminus, the first and longest of the RAMP1 helices, aR1, spans
residues 28–51, but is interrupted by the disulfide bond betweend All rights reserved
Figure 2. Superposition of CLR/RAMP1 with the Ectodomain
Structures of PTH1 and GIP1
PTH1 Receptor (Pioszak and Xu, 2008) (pdb id: 3c4m) and GIP1 receptor
(Parthier et al., 2007) (pdb id: 2qkh). PTH (gold) andGIP (green) are each super-
imposed on CLR (cyan). RAMP1 is shown in magenta and is not used for the
alignment. Rmsds for backbone atoms of PTH1-R and GIP1-R ECDs with
the CLR ECD are 1.35 and 2.56 A˚, respectively. The helical peptides
glucose-dependent insulinotropic polypeptide (GIP) and parathyroid hormone
(PTH) are shown as transparent cylinders. See also Figure S2.
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Crystal Structure of the CGRP Receptor ECD ComplexC40 and C72. Although the backbone dihedral angles are in
the a-helical range for all residues in this helix, the backbone
carbonyls of residues 37 and 38 do not form intrahelical H-bonds
with the backbone nitrogens. Helix aR1 is followed by a short
3-10 helix (residues 53–56) followed by helix aR2 (residues
62–79), a short loop, and helix aR3 (residues 86–101) at the
C terminus.
Numerous interactions, both electrostatic and hydrophobic in
nature, stabilize the CLR/RAMP1 heterodimer, and occur
predominantly between helix aC1 of CLR and helices aR2 and
aR3 and the C-terminal loop region (102–108) of RAMP1.
Some of the key interactions are shown in Figure 1B. Viewed
from the near end of the CLR helix, an extensive hydrogen
bonding network is observed involving two CLR Gln side chains.
The CLR Gln54 side-chain carbonyl interacts with the backbone
amides of RAMP1 Arg102 and Cys104, while the CLR Gln50
side-chain carbonyl bonds with the side-chain and backbone
amide groups of RAMP1 residues His97, Phe101, and Pro105,
respectively. Additional side-chain-side-chain hydrogen
bonding occurs between CLR residues Tyr49 and Gln45 with
RAMP1 residues Asp90 (helix aR3) and Tyr66 (helix aR2),
respectively. Also visible are hydrophobic interactions between
CLR Tyr46 and both RAMP1 Trp59 (loop connecting helix
aR2 and helix aR3) and Phe101 (helix aR3). A complete list
of CLR-RAMP1 helix-helix interactions is provided in Table 2.
The buried surface area arising from complex formation
is >1000 A˚2 (Figure 1B). Despite this large interaction surface,
when compared with the X-ray structure of the RAMP1 homo-
dimer (Kusano et al., 2008), formation of a heterodimer with
CLR does not cause a major rearrangement of RAMP1 structural
features; the secondary structural elements, disulfide bonds,
and interhelical contacts found in the RAMP1 homodimer are
largely conserved in the complex with CLR.Structure 18, 1083–10It is important to note that although we classify this
CLR/RAMP1 binary complex structure as unliganded, examina-
tion of the electron density map reveals that eleven C-terminal
residues of RAMP1 from one receptor complex occupy part of
the ligand binding site of an adjacent receptor complex in the
crystal lattice (Figure 1C). This interaction is strictly crystallo-
graphic in nature owing to the truncated construct used for
crystallization; for a full-length receptor, this sequence would
constitute part of the juxtamembrane region. The bound tail-
piece, corresponding to residues 109–117, occupies a site
primarily on the CLR face, but adjacent to the interface with
RAMP1. The peptide runs through a channel beginning near
Arg38 of CLR, up toward a deep pocket of hydrophobic residues
on RAMP1, then crosses the Trp72 finger of CLR, below the
small molecule binding pocket (described in the next section),
leaving the C-terminal RAMP1 Ser117 contacting a shallow
hydrophobic pocket. A sulfate ion is bound to CLR Thr122 in
this complex, but not in liganded complexes. Although the
observed protein-protein contacts are not biologically relevant,
these interactions may be useful for the design of novel antago-
nists with alternative binding modes.
Receptor Recognition Elements for Antagonist Binding
The CLR/RAMP1 ECD complex used in this study has been
shown, particularly for small molecule and peptide antagonist
binding, to be a valid functional surrogate for the full-length
receptor complex (Koth et al., 2010). For example, using radioli-
gand binding methods, olcegepant (Figure 3) binds to the full-
length receptor with low picomolar affinity (KD = 45 pM (Schindler
and Doods, 2002); Ki = 14 pM (Doods et al., 2000)). Olcegepant
also shows high affinity for the ectodomain complex (as mea-
sured by surface plasmon resonance), with a dissociation
constant below the limit of detection (KD < 20 nM) (Koth et al.,
2010). Crystals of olcegepant with the ectodomain complex
contained two CLR/RAMP1 complexes per asymmetric unit.
These crystals were unusual in that olcegepant only bound to
one of the twoCLR/RAMP1 pairs, with the second ligand binding
site occupied by the C terminus of the RAMP1 from an adjacent
complex. The two binding sites in this crystal form were very
similar structurally, with pairwise root mean square deviations
(rmsds) of 1.48 A˚ between the two complexes in the asymmetric
unit, and 1.18 A˚ for atoms within <4.5 A˚ of the bound olcegepant
molecule (superpositions are shown in Figure S1 available on-
line). The structure of olcegepant bound to the CGRP receptor
ectodomain complex (Figure 4) reveals the key drug-protein
interactions that contribute to antagonist potency. The drug
molecule binds in an extended conformation (Figures 4C and
4D), stretching 18 A˚ from a hydrogen bond donor site at
Thr122 of CLR, across the interface with RAMP1, and deep
into a hydrophobic binding pocket formed by helix aC1 of CLR
and helix aR2 of RAMP1. RAMP1 residues Trp74 (helix aR2)
and Trp84 (in the loop connecting RAMP1 helices aR2 and
aR3) form the ceiling and back surface of the hydrophobic
binding pocket (Figure 4D). The quinazolinone moiety of olcege-
pant forms a hydrogen bond donor-acceptor pair with the
backbone NH and carbonyl of CLR Thr122. The side chain of
CLR Trp72 undergoes a rotation of 70 compared with the
unliganded complex, forming a ‘‘Trp shelf’’ on which the piperi-
dine ring of olcegepant stacks. Olcegepant branches at the93, September 8, 2010 ª2010 Elsevier Ltd All rights reserved 1085
Table 1. X-Ray Refinement Statistics
SeMet High Resolution SeMet Peak Olcegepant Telcagepant
Wavelength 1.000 0.9804
Space group P3221 P3221 C2221 C2221
Cell dimensions a = b = 118.2
c = 225.8
a = b = 118.2
c = 225.8
a = 73.3
b = 119.1
c = 137.2
a = 77.9
b = 118.2
c = 133.3
No. of reflections 130,149 321,993 340,718 310,841
No. of unique reflections 39,161 34,485 30,514 10,399
Completeness (%) 84.9 (36.0) 79.6 (28.5) 86.9 (51.5) 73.6 (12.1)
Rmergea 0.065 (0.319) 0.099 (0.403) 0.073 (0.424) 0.066 (0.438)
I/sigma 23.8 (2.6) 21.3 (1.7) 20.2 (2.1) 18 (1.6)
Redundancy 3.3 (2.4) 3.3 (2.4) 4.6 (3.1) 4.1 (1.3)
Resolution (A˚) 2.79 3.00 2.10 2.9
Rwork/Rfree 0.21/0.24 NA 0.21/0.23 0.23/0.27
Number of atoms 5537 NA 3118 2832
Protein 5404 NA 2902 2698
Ligand/ion 221 NA 216 134
Water 53 NA 131 40
B factors
Wilson/Mean
64.2/97.4 NA 32.8/43.1 62.7/91.53
Rmsd
Bond lengths (A˚) 0.01 NA 0.01 0.01
Bond angles () 1.06 NA 1.02 1.03
Ramachandran plot (%)
Most favored 92.5 NA 93.4 94.1
Additionally allowed 7.1 NA 6 5.9
Generously allowed 0.3 NA 0.6 0
Disallowed 0 NA 0 0
SAD structure solution
Resolution cutoff (A˚) 6.0
No. anomalous sites found 9 (of 12)
Figure of merit (to 3.2 A˚) 0.212
Phasing power (to 3.2 A˚) 0.717
aRsym = SSj jIj  < I > j/SSjIj.
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Crystal Structure of the CGRP Receptor ECD Complexamide linkage, extending both to the rear of the binding pocket,
where the hydroxyl of the dibromotyrosyl group interacts via a
water-mediated hydrogen bond with both the CLR aC1 (Arg38
3-NH) and RAMP1 aR2 (Arg67 CO) helices, and toward the
solvent-exposed surface, where the carbonyl of the second
amide-linkage forms a hydrogen bond with the indole NH of
CLR Trp72. The lysine 6-amino terminus of olcegepant forms
a salt bridgewith the side-chain carboxyl of RAMP1 Asp72, while
the indole of RAMP1 Trp74 stacks with the aliphatic portion.
Finally, the terminal pyridyl stacks with the aromatic ring of
CLR Phe92, while also making a hydrogen bond with the side-
chain carboxyl of CLR Asp94.
While it is clear that multiple ligand:protein interactions
contribute to the subnanomolar potency of olcegepant, this is
achieved with a relatively high molecular weight molecule
(MW= 870 Da). Based on the typical physicochemical properties
of large drug molecules, it is not surprising that olcegepant is not
orally bioavailable. Alternatively, telcagepant (MW = 566 Da)1086 Structure 18, 1083–1093, September 8, 2010 ª2010 Elsevier Lt(Figure 3), has demonstrated superior pharmacokinetic proper-
ties (Paone et al., 2007), possessing oral bioavailability and effi-
cacy at several doses (Ho et al., 2008a, 2008b). With KD = 1.9 nM
(Moore et al., 2009), telcagepant is not as potent against
full-length receptor as olcegepant, but binds with KD < 20 nM
to the ectodomain complex (Koth et al., 2010). Although initial
attempts to grow co-crystals of telcagepant with the ectodomain
complex failed, we were able to use the crystals of olcegepant/
CLR/RAMP1 and soak telcagepant into the unoccupied ligand
binding site of the second CLR/RAMP1 heterodimer in the unit
cell (displacing the RAMP1 C-terminal peptide). The structure
of telcagepant bound to the CGRP ectodomain complex is
shown in Figure 5A. Despite its lowerMW, telcagepant maintains
a similar binding topology to olcegepant, spanning the 18 A˚
distance from the Thr122 hydrogen bond donor-acceptor site
on CLR to the hydrophobic pocket on RAMP1. A superposition
of the two ligands in the CLR/RAMP1 binding site is shown in
Figure 5C. The structure reveals a slightly different topology atd All rights reserved
Table 2. Helix-Helix and Helix-Loop Interactions between CLR
and RAMP1
No Ligand Ligand
Hydrogen bond T43 - W59
Y49 - D90
Q50 - H97, F101, P105
Q54 - C104, R102
Q45 – Y66
T43 - W59
Y49 - D90
Q50 - H97, F101, P105
Q45 – Y66
T68 – D90
E47 - G108
N39 - R67
Hydrophobic
interaction
M42 - Y66, A70, R67
Y46 - W59, F101, Y66
Y49 - F93, L94, H97
M53 - L94, G98, R102
R119 - F83
M42 - Y66, A70, R67
Y46 - W59, F101, Y66, G108
Y49 - F93, L94, H97
M53 - L94, G98, R102
R119 - F83
Salt Bridge R38 - D71 R38 - D71
For each pair, the first residue listed is from CLR; the second (or addi-
tional) residues are from RAMP1. The olcegepant-liganded structure
(2.1 A˚ resolution) was used for the analysis. In that complex, there are
two CLR/RAMP1 complexes in the asymmetric unit, with the small mole-
cule binding site of one complex occupied by olcegepant, and the other
vacant.
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Crystal Structure of the CGRP Receptor ECD Complexthe hydrogen bond donor-acceptor site (Figure 5D), where the
azabenzimidazolone ring system of telcagepant forms an
additional weak hydrogen bond with the backbone carbonyl of
CLR Thr122. As in olcegepant, the piperidyl moiety forms an
edge-to-face stack with CLR Trp72. The carbonyl of the
seven-membered caprolactam ring forms a weak hydrogen
bond with the indole NH of CLR Trp72, analogous to the amide
group in olcegepant. While binding of the dibromotyrosyl group
of olcegepant relies on both hydrophobic and electrostatic
interactions, binding of the difluorophenyl group of telcagepant
appears to be primarily hydrophobic in nature. Here, RAMP1
Trp74 and RAMP1 Trp84 similarly frame the hydrophobic
pocket, with the difluorophenyl reaching deeper into the
pocket than the dibromotyrosine, displacing a bound water
molecule and making hydrophobic contacts with the side chain
of CLR Met42, a residue previously implicated in telcagepant
binding (Miller et al., 2010). Additional hydrophobic contactsFigure 3. Chemical Structures of Olcegepant and Telcagepant
Olcegepant (Compound 1) is shown on the left and telcagepant (Compound 2) o
Structure 18, 1083–10arise between the ligand trifluoroethyl and the side chain of
CLR Ile41.
The efficiency of ligand:protein interactions can differentiate
a potent antagonist with poor pharmacokinetic properties
from an orally bioavailable drug molecule. Although telcagepant
(KD = 1.9 nM (Moore et al., 2009); MW = 566 Da) is not as potent
as olcegepant (KD = 45 pM (Schindler and Doods, 2002);
MW = 870 Da), at a significantly lower MW it makes fewer, but
more productive contacts with the receptor ectodomain. For
telcagepant, increased binding efficiency results from an addi-
tional hydrogen bond from the azabenzimidazolone group at
the CLR Thr-122 site, as well as from replacement of the dibro-
motyrosyl group of olcegepant with a lower MW difluorophenyl
group. The difluorophenyl extends deeper into the RAMP1
hydrophobic pocket and makes additional hydrophobic
contacts with CLR and RAMP side chains, while displacing a
bound water molecule, potentially enhancing both the enthalpic
and entropic components, respectively, of the ligand binding
energy (compared with olcegepant) for this receptor subsite.
Comparison with Other Class B GPCR Ectodomains
and Ligand Binding Sites
The structure of CLR in the ectodomain complex aligns well with
other class B GPCRs. The alignment is particularly strong for the
GIP and PTH receptor domains, which possess a helix similar in
length to helix aC1 of CLR (Figure 2). The disulfide-stabilized
finger-like motif is also well defined and conserved across all
the published structures. It is difficult to predict whether CGRP
binds in a helical conformation similar to the peptides bound to
the GIP (Runge et al., 2008), PTH (Pioszak and Xu, 2008),
CRFR1 (Pioszak et al., 2008), CRFR2 (Grace et al., 2007), and
PAC1 (Sun et al., 2007) receptors. Although PTH, GIP, and as-
tressin bind with the same approximate helix orientation, they
occupy different positions on one face of the ECD, whereas
PACAP binds PAC1-R on the opposite face (Figure S2). The
olcegepant and telcagepant crystal structures suggest that a
PACAP-like peptide binding orientation can be ruled out, since
these antagonists are competitive with the functional mode of
binding for CGRP. Similarly, an astressin-like conformation
(Figure S2) is less likely since it is hard to envision how RAMP1n the right.
93, September 8, 2010 ª2010 Elsevier Ltd All rights reserved 1087
Figure 4. Structure of the Olcegepant/CLR/
RAMP1 Liganded Complex.
(A) Olcegepant (yellow) binds at the interface of
CLR (cyan) and RAMP1 (magenta). Dashed dark
lines indicate hydrogen bonds to the backbone
of Thr122 and side chain of Asp94 on CLR, the
side chain of RAMP1 Asp71, and a water-medi-
ated hydrogen bond at the CLR-RAMP1 interface
involving CLR Arg38 and RAMP1 Arg67.
(B) The Fo-Fc electron density map contoured at
3s is superimposed on the structure of olcegepant
(yellow).
(C) CLR/RAMP1 is shown in surface representa-
tion, olcegepant is shown in stick representation.
Coloring for olcegepant: C, yellow; O, red; N,
blue; Br, green.
(D) Detail of olcegepant binding pocket.
See also Figure S1.
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Crystal Structure of the CGRP Receptor ECD Complexcould confer specificity at such a long distance from the peptide.
A more likely peptide binding orientation might resemble that of
GIP or PTH, where the peptide C terminus comes into close
contact with the Phe83-Pro85 loop of RAMP1. In such an orien-
tation, RAMP1-peptide interactions could dictate peptide
(CGRP versus AM) selectivity and would easily be blocked by
olcegepant or telcagepant.
Utility of the CLR/RAMP1 Ectodomain Structure
for Ligand Design
Although we have taken a reductionist approach in crystallizing
the soluble ectodomain complex rather than the full-length
GPCR-accessory protein complex, the observation that the
CLR/RAMP1 heterodimer binds olcegepant and telcagepant
with low nanomolar or tighter affinity (Koth et al., 2010) gave us
confidence that the ectodomain complex can serve as a useful
model for drug lead optimization. Fortunately, much SAR work
has been published, which allows a retrospective analysis of
compound potency as it relates to the key structural features
of the CLR/RAMP1 ectodomain complex. Specifically, increases
in potency found for compounds on the optimization path to
olcegepant (Rudolf et al., 2005) (Figure 6A) and telcagepant
(Paone et al., 2007; Shaw et al., 2007) (Figure 6B) can be rational-
ized based on the quality of interactions of the small molecule
with pharmacophore recognition sites on CLR/RAMP1. In the
case of olcegepant, compounds were selected to optimize
electrostatic interactions with the hydrogen bond donor-
acceptor site at CLR Thr122, while for telcagepant, altering the
positioning and stereochemistry of substituents on the capro-
lactam ring resulted in increased potency through better access
to the RAMP1 hydrophobic pocket.1088 Structure 18, 1083–1093, September 8, 2010 ª2010 Elsevier Ltd All rights reservedRudolf et al. (2005) provide a detailed
description of the chemical design strate-
gies used leading to the synthesis of
olcegepant. Using the ligand-protein
interactions and conformation of olcege-
pant bound to CLR/RAMP1 (Figures 4A
and 5D) as a basis for evaluating each
ligand, the lower potencies of com-
pounds 12 and 16 (Figure 6A) can beexplained by differences in the interactions these compounds
make with the receptor. For example, first-generation lead
compound 12 lacks both the piperidyl amide (important for
hydrophobic stacking with CLR Trp72) and the hydrogen bond
donor-acceptor pair found in olcegepant. The ethyl linker con-
necting the 2-methoxyphenyl group and amide nitrogen of
compound 12 (IC50 = 1 mM) is not long enough to position the
former group appropriately for hydrogen bonding with the
Thr122 backbone carbonyl and amide NH. Without these key
interactions, it is not surprising that this compound would be
a weak binder. Alternatively, compound 16 (IC50 = 44 nM)
possesses the same piperidyl amide linker as in olcegepant
but is linked to a 2(3H)-benzoxazolone ring system containing
two hydrogen bond donors (shown schematically in Figure 6A).
Here, the piperidyl amide can form a hydrophobic stacking inter-
action with Trp72 of CLR, and is the correct length for positioning
the benzoxazolone ring oxygen near the Thr122 backbone NH.
This single hydrogen bonding interaction, along with a better
hydrophobic stacking interaction due to the piperidyl versus
ethyl linker, results in a 22-fold increase in potency compared
to compound 12. The most potent compounds (IC50 < 5 nM) in
this series, including the exquisitely potent olcegepant
(Figure 6A, compound 19) (IC50 = 30 pM), possess a piperidyl
amide, extending to a donor-acceptor pair that forms hydrogen
bonds with the Thr122 backbone carbonyl and amide groups
(Figures 5D and 6).
Several papers describe the evolution of the caprolactam
class of CGRP antagonists leading to the clinical compound
telcagepant (Paone et al., 2007; Shaw et al., 2007). The first
study (Shaw et al., 2007) describes optimization of the stereo-
chemistry and substitution pattern on the central caprolactam
Figure 5. Structure of the Telcagepant/
CLR/RAMP1 Liganded Complex and Com-
parison of Olcegepant and Telcagepant
Binding
(A) CLR/RAMP1 is shown in ribbon representa-
tion; telcagepant is shown in stick representation.
Coloring for telcagepant: C, green; O, red; N, blue;
S, yellow; F, light blue. Protein side-chain carbons
are colored cyan and magenta for CLR and
RAMP1, respectively. Protein heteroatoms are
colored: O, red; N, blue; S, yellow.
(B) The Fo-Fc electron density map contoured at
3s is superimposed on the structure of telcage-
pant. Coloring for telcagepant: C, yellow; O, red;
N, blue; F, light blue.
(C) Overlay of the structures of olcegepant and
telcagepant at the antagonist binding site. Both
ligands are shown in stick representation. Coloring
for olcegepant:C, yellow;O, red;N, blue; Br, green.
(D) Details of hydrogen bond donor-acceptor inter-
actions for olcegepant and telcagepant. Dashed
dark lines indicate hydrogen bonds to the back-
bone of Thr122 on CLR.
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Crystal Structure of the CGRP Receptor ECD Complexgroup. Specifically, the hydrogen bond donor-acceptor group
was limited to quinazolinone (as found in olcegepant), and the
stereochemistry and position of the phenyl group on the
seven-membered 1-cyclopropylmethyl caprolactam ring were
then modified. Several 7-, 6-, and 5-phenyl-substituted com-
pounds were synthesized. The 7-phenyl-substituted com-
pounds were the least active, and the most potent of these is
shown in Figure 6B (top). Examination of the X-ray structure
of telcagepant bound to the CLR/RAMP1 binding pocket
suggests that changing the position of ring attachment from
the 6- to either a 7- or 5- position on the caprolactam would
no longer provide an optimal vector for this group to access
the RAMP1 hydrophobic pocket. In fact, the 7-phenyl capro-
lactam would not be able to access the pocket at all, which
explains the low affinity observed for this compound (Ki =
689 nM) (Figure 6B, left). The 6-phenyl-substituted caprolactam
(3R,7S stereochemistry) (Figure 6B, middle), however, showed
28-fold improvement in potency. 5-Phenyl-substituted com-
pounds, while still active, displayed a slight loss in potency.
Importantly, the structures can easily explain the absolute
requirement for a 3R configuration at C-3 of the caprolactam
([3R,6S], Ki = 25 nM; [3S,6R], Ki = 5828 nM) (Shaw et al.,
2007). Inversion of the stereochemistry to a 3S,6R configuration
results in the caprolactam favoring pseudoaxial placement
of either the amide or the phenyl substituent versus the linear
pseudoequatorial placement preferred by the (3R,6S) diaste-
reomer. The result is a highly strained caprolactam ring that is
unable to adopt an extended conformation required for
placement of the caprolactam C6 phenyl in the CLR/RAMP1
hydrophobic pocket.Structure 18, 1083–1093, September 8, 2010 ªThe CLR/RAMP1 Ectodomain
Structures as a Context for
Interpretation of Functional Data
Previous studies of ectodomain function
using full-length receptor have examined
the species selectivity of CGRP antago-nists, as well as antagonist binding specificity mediated by
different RAMP subtypes. Mutational and deletion analyses
have identified residues critical for receptor function, including
heterodimer formation, transport to the plasma membrane and
antagonist binding. Given this large body of functional data, it
is useful to assess how the current structures support our current
understanding of CGRP receptor biology.
For example, 125I-CGRP radioligand binding assays indicated
both olcegepant and telcagepant exhibit a higher affinity for the
human CGRP receptor than the rat receptor. The selectivity
observed is >100-fold for olcegepant (Doods et al., 2000),
and >1500-fold for telcagepant (Salvatore et al., 2008). For olce-
gepant, this has been attributed to a sequence difference at
RAMP1 residue 74 (Hay et al., 2006; Mallee et al., 2002), which
is a tryptophan in primates, but a lysine residue in rat andmouse.
The ectodomain complex structure provides a clear rationale for
the observed selectivity. RAMP1 Trp74, in the orientation shown
(Figures 4C, 4D, and 5A), forms the ‘‘ceiling’’ of the hydrophobic
pocket. Replacement of this residue with a lysine would remove
a key component of the RAMP1 hydrophobic pocket, both
reducing the total ligand-protein hydrophobic surface, and by
nature of the longer, charged side chain, sterically hinder access
to the binding pocket. While olcegepant has additional functional
groups, such as the piperazylpiperidine and 6-aminohexyl moie-
ties, which might compensate for the decreased binding at
RAMP1 Trp74, the smaller telcagepant molecule does not, and
this could account for the greater observed difference in affinity
for telcagepant between the human and rodent receptors.
The structure of CLR/RAMP1 may also explain the exquisite
selectivity of olcegepant for the CGRP receptor versus the2010 Elsevier Ltd All rights reserved 1089
Figure 6. Structure-Activity Relationships for Olcegepant and Telcagepant Lead Optimization
(A) SAR of olcegepant derivatives. Compounds are labeled with the compound numbers listed in Table 1 of Rudolf et al. (2005). Two dimensional cartoon
diagrams show putative hydrogen bonding schemes for each compound.
(B) SAR of telcagepant derivatives. Ki and IC50 values are taken from Shaw et al. (2007) and Paone et al. (2007). The left and middle structures correspond to
Compounds 16 and 20 from Shaw et al. (2007), while the compound on the right is compound 38 (telcagepant) from Paone et al. (2007).
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Crystal Structure of the CGRP Receptor ECD ComplexAM1 (CLR/RAMP2) and AM2 (CLR/RAMP3) receptors (Hay et al.,
2003). While RAMP1 contains a Trp at position 74, RAMP2 and
RAMP3 both contain a nonconservative Glu. Other RAMP1
residues (Ala70, Asp71, His75, Phe83, Trp84, and Pro85) also
contact olcegepant and may play a minor role in conferring
selectivity, but these residues are either identical or conserved
across the three RAMP protein sequences. This strongly impli-
cates residue 74 as the key determinant of olcegepant selectivity
for the CGRP receptor.
The structures also provide a deeper understanding of pre-
vious mutational and deletion analyses with CLR and RAMP1.
Several studies have implicated CLR residues (23–60) as neces-
sary for heterodimer formation and transport of the CLR/RAMP1
complex to the plasma membrane (Barwell et al., 2010; Ittner
et al., 2005). In one study (Ittner et al., 2005), a chimeric receptor
was constructed where homologous residues (29–104) of PTH
receptor were changed to those found in CLR (residue 23–60),
resulting in CLR/RAMP1 heterodimerization and cotransport to
the plasmamembrane. In another study, alanine scanning muta-
genesis was used to identify residues involved in CGRP binding,
cell surface expression, and receptor internalization (Barwell
et al., 2010). In the latter work, Gln45Ala and Tyr49Ala signifi-
cantly impaired cell surface expression. The CLR construct1090 Structure 18, 1083–1093, September 8, 2010 ª2010 Elsevier Ltused in the present crystallographic structure determination
consisted of residues 23–133, with observable electron density
starting at residue 34. Residues 34–60 are highlighted in red in
Figure S3 and encompass all of helix aC1 as well as part of the
following loop. Contacts between helix aC1 (the single helix in
CLR) and helices aR2 and aR3 of RAMP account for most of
the buried surface in the heterodimer, and thus are the primary
structural elements driving dimerization with RAMP1. Mutations
affecting the helix-helix interface, such asGln45Ala and Tyr49Ala
(Barwell et al., 2010), would be expected have profound conse-
quences on the assembly of a functional CLR/RAMP1 complex.
Deletion mutagenesis of RAMP1 (Kuwasako et al., 2003) has
similarly identified residues spanning helix aR3 as critical for
receptor function. The deletion mutants studied (Figure S4)
formed heterodimers and were transported to the cell surface
but did not bind 125I-CGRP and were not functional in a cell-
based cAMP assay. Deletion of segments of RAMP1 helix aR3
(D91-94, D96-100) and the loop near the critical disulfide at
Cys104 (D101-103), would cause disruptions of regular helical
secondary structure and severe distortions of the geometry at
the putative peptide binding site, including Trp 84, which also
helps form the antagonist binding pocket. However, key
contacts for heterodimerization between RAMP helix aR2 andd All rights reserved
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Crystal Structure of the CGRP Receptor ECD ComplexCLR helix aC1 would be preserved, enabling normal transport of
CLR/RAMP1 to the cell surface.
In summary, we have used a reductionist approach to crystal-
lize the complex of the extracellular domains of CLR andRAMP1.
The structures, the first determined for a class B GPCR with
a RAMP protein, reveal how the extracellular domain of the
accessory protein binds and modulates the antagonist-binding
activities of CLR. Moreover, the structures provide a basis for
modeling the interactions of other RAMP proteins with this
important therapeutic class B subfamily.
The structures of the important clinical antagonists olcegepant
and telcagepant bound to the CLR/RAMP1 ECD complex repre-
sent the first for any small molecules bound to a class B GPCR.
As such, they provide the first models for structure-based design
of new CGRP receptor-targeted pain therapeutics, and clearly
illustrate why CGRP antagonist design has been such a daunting
drug design problem. In order to meet desired potency and
receptor selectivity criteria, antagonist molecules must be of
sufficient length to span the distance between the hydrogen
bond donor-acceptor subsite on CLR and the hydrophobic
pocket on RAMP1. Antagonism via an olcegepant or telcage-
pant-like binding mode thus imposes a minimum molecular
weight requirement. Beyond potency, migraine drugs must
also possess physical properties consistent with the desired
pharmacokinetic profile. However, such drug-like properties
are historically difficult to achieve as molecular mass increases.
Although the physicochemical properties for the ideal CGRP
receptor-targeted migraine therapeutic run counter to the strin-
gent pharmacophore requirements of the receptor binding site,
subnanomolar antagonists with MW as low as 460 Da have
been reported (Stump et al., 2009; Theberge et al., 2008),
although none have been successful in a clinical setting.
Despite lacking the juxtamembrane and transmembrane
domains of CLR and RAMP1, the crystallographic models
provide an appropriate context for interpretation of previously
reported studies examining chemical structure-activity relation-
ships (SAR), species selectivity, and antagonist binding
specificity. The structures also reinforce the conclusions of
mutational and deletion analyses that identify residues critical
for receptor function, including heterodimer formation, transport
to the plasma membrane and antagonist binding.
In conclusion, the structures presented provide insight into
the molecular mechanism of CGRP receptor antagonism and
establish a new framework for addressing the formidable
challenges in structure-based design of CGRP-directed pain
therapeutics.EXPERIMENTAL PROCEDURES
Purification and Refolding of CLR/RAMP1 Extracellular Domains
Details of cloning, expression, refolding, and purification of the CLR and
RAMP1 extracellular (ECD) domain complex have been published elsewhere
(Koth et al., 2010). In brief, ectodomain constructs for CLR23-133 and
RAMP26-117 were cloned into pET28b with an N-terminal hexahistidine tag
followed by a thrombin cleavage site. Proteins were expressed in Rosetta
DE3 cells by induction (at AU600 of 0.5–0.8) with 0.5 mM isopropyl-b-D-thioga-
lactopyranoside for 3 hr at 37C. The selenomethionine-labeled protein
complex was prepared by growing cells in M9 SeMET high-yield media
(MD045004-12L) purchased from Shanghai Medicilon Inc. (Shanghai, China).
After cell harvest and lysis, inclusion bodies were prepared and solubilizedStructure 18, 1083–10in 6 M guanidine hydrochloride containing 100 mM DTT, 50 mM sodium phos-
phate (pH 8.0). Following dialysis to remove DTT, the proteins were co-re-
folded to generate the CLR23-133/RAMP26-117 ECD complex by mixing equi-
molar amount at a concentration of 0.1–0.2 mg/ml and dialyzed in a buffer
containing 1 M arginine, 50 mM sodium phosphate (pH 8.0), and 5 and
1 mM reduced and oxidized glutathione, respectively. A final dialysis was per-
formed to remove arginine. The supernatant was centrifuged and filtered
before resolving by anion exchange, and the co-eluted CLR/RAMP1 was
pooled and loaded on an S200 gel filtration column. The purified complex
was pooled and concentrated to 15–20 mg/ml for crystallization.
Crystallization, Structure Determination, and Analysis
Crystalsweregrownusing thehangingdropvapordiffusionmethodovera reser-
voir containing 1–1.3 M ammonium sulfate, 6%–8% dioxane, 60–80 mM MES
(pH 6.5; 60%–80% Classics #50, Hampton Research, Aliso Viejo, CA), plus
10 mM Tris (pH 8.5) and 200 mM sodium nitrate. Crystals appeared in about
2 weeks and were typically harvested after 4 weeks. To prepare the crystals
for data collection, they were transferred to 2.1 M sodium malonate (pH 7.0)
for approximately 5 min and subsequently frozen in liquid nitrogen. The diffrac-
tion data was collected at beamline 5.0.2 of the Advanced Light Source in
Berkeley CA. The diffraction data were merged and scaled using HKL2000.
The crystals belonged to the space group P3221 but were partially twinned
with a twinning fraction of 0.3. The diffraction intensities were detwinned using
CCP4’s Detwin program. Two data sets were used for structure determination:
0.9804 A˚ (peak), and 1.0 A˚ (high-resolution data set). Initial seleno-methionine
sites were found with the Se-Met peak data set at 6 A˚ resolution cutoff using
ShelXD. Subsequently, autoSHARP was used (using the Se-Met peak data
set at 3.2 A˚) to optimize the seleno-methionine sites. The phasing statistics
showed that the initial phase information extended to 5.8 A˚. This resolution
was used as the starting point for density modification and phase extension
by autoSHARP. The obtained phases were then used to calculate a 2.8 A˚ elec-
tron density map with the Se-Met High Resolution data set for model building.
Subsequent rounds of building in Quanta and Coot and refinement in
autoBUSTER resulted in a final model that contained four CLR/RAMP1 heter-
odimers in the asymmetric unit of which one was very disordered.
To obtain crystals of the CLR/RAMP1 complex with olcegepant, the
compoundwasmixedwith unlabeledCLR/RAMP1complex prior to crystalliza-
tion in a 1:4 (protein: compound) molar ratio. Crystals were obtained by mixing
0.6 ml protein with 0.3 ml reservoir solution containing 1–1.3 M ammonium
sulfate, 6%–8% dioxane, 60–80 mM MES (pH 6.5; 60%–80% Classics #50,
Hampton Research, Aliso Viejo, CA), plus 0.4 M potassium thiocyanate. The
crystals appeared after approximately 3 weeks and were typically harvested
after 6 weeks. Prior to data collection, the crystals were transferred to 2.1 M
sodium malonate (pH 7.0) for about 5 min and subsequently frozen in liquid
nitrogen. In order to obtain the complex of CLR/RAMP1with telcagepant, crys-
tals of the olcegepant CLR/RAMP1 complex were transferred to a mixture
containing 2.1Msodiummalonate (pH7.0) and 0.2mM telcagepant (dispensed
from a 10mMDMSOstock solution). The crystal was soaked for approximately
16 hr prior to freezing in liquid nitrogen. The data was collected at beamline
5.0.2 (olcegepant) and 5.0.3 (telcagepant) of the Advanced Light Source in
Berkeley, CA, indexed, and scaled in HKL2000 and the structure was solved
bymolecular replacement usingunligandedCLR/RAMP1as thestartingmodel.
The crystals belonged to the space group C2221 with two CLR/RAMP1 heter-
odimers in the asymmetric unit; however, only one of them contained an
olcegepant molecule in the ligand-binding site. The crystals that were soaked
with telcagepant contained olcegepant in one ligand binding site, and telcage-
pant in the other. After several rounds of refining in autoBUSTER and rebuilding
in Coot a final structure was obtained with a R/Rfree of 0.21/0.23 (olcegepant)
and 0.23/0.27 (telcagepant). Structure alignment of CLR with other class B
GPCRs was calculated in Pymol (Delano Scientific LLC, Palo Alto, CA).
Buried surface area was also determined in Pymol and calculated as Buried
Surface AreaCOMPLEX = [(AREARAMP1 + AREACLR) – AREACOMPLEX]/2.
ACCESSION NUMBERS
Atomic coordinates and structure factors have been deposited in the Protein
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